OlympiAD

NCT02000622 📎

Regimen

Experimental
Olaparib 300 mg BID orally until progression.
Control
Physician's choice single-agent chemotherapy (capecitabine, eribulin, or vinorelbine).

Population

HER2-negative metastatic breast cancer with germline BRCA1/2 pathogenic variant, up to 2 prior chemotherapy lines for metastatic disease (hormone therapy in HR+ allowed).

Key finding

OlympiAD first demonstrated PARP inhibitor superiority over chemotherapy in germline BRCA-mutated HER2-negative metastatic breast (NCCN category 1 preferred; FDA approved January 2018). TNBC subgroup comprised ~50%.

Source: PMID 28578601

Timeline

  • Publication: 2017 Aug 10

Guideline citations

  • NCCN BREAST